Related references
Note: Only part of the references are listed.Emerging trends in the diagnosis and treatment of acromegaly in Canada
Sophie Vallette et al.
CLINICAL ENDOCRINOLOGY (2013)
Novel pathway for somatostatin analogs in patients with acromegaly
Monica R. Gadelha et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2013)
Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying?
Claudia Ramirez et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Pre-surgical treatment with somatostatin analogues in patients with acromegaly: The case against
M. Losa et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2012)
Pre-surgical treatment with somatostatin analogues in patients with acromegaly: The case for
D. Ferone et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2012)
Improvement of cardiac parameters in patients with acromegaly treated with medical therapies
Annamaria Colao
PITUITARY (2012)
Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
Andrea Giustina et al.
PLOS ONE (2012)
Acromegaly: Role of Surgery in the Therapeutic Armamentarium
Gerardo Guinto et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2012)
Safety Review: Dose Optimization of Somatostatin Analogs in Patients with Acromegaly and Neuroendocrine Tumors
William H. Ludlam et al.
ADVANCES IN THERAPY (2011)
Efficacy and Safety of Radiotherapy in Acromegaly
Baldomero Gonzalez et al.
ARCHIVES OF MEDICAL RESEARCH (2011)
Recommendations of Neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism for diagnosis and treatment of acromegaly in Brazil
Leonardo Vieira Neto et al.
ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA (2011)
Resistance to Somatostatin Analogs in Acromegaly
Annamaria Colao et al.
ENDOCRINE REVIEWS (2011)
Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone
Aart-Jan van der Lely et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Place of Cabergoline in Acromegaly: A Meta-Analysis
Laure Sandret et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Medical therapy in acromegaly
Mark Sherlock et al.
NATURE REVIEWS ENDOCRINOLOGY (2011)
Current management practices for acromegaly: an international survey
A. Giustina et al.
PITUITARY (2011)
Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review
Maria Fleseriu
PITUITARY (2011)
Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial
Zhi-gang Mao et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010)
Approach to the Patient with Persistent Acromegaly after Pituitary Surgery
Laurence Katznelson
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Management of acromegaly in Latin America: expert panel recommendations
Ariel Barkan et al.
PITUITARY (2010)
Medical Therapy of Acromegaly Efficacy and Safety of Somatostatin Analogues
Richard A. Feelders et al.
DRUGS (2009)
ACROSTUDY: the first 5 years
Peter J. Trainer
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Medical Therapy in Patients with Acromegaly: Predictors of Response and Comparison of Efficacy of Dopamine Agonists and Somatostatin Analogues
M. Sherlock et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study
Annamaria Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Guidelines for Acromegaly Management: An Update
S. Melmed et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Acromegaly pathogenesis and treatment
Shlomo Melmed
JOURNAL OF CLINICAL INVESTIGATION (2009)
Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide
N. Karavitaki et al.
CLINICAL ENDOCRINOLOGY (2008)
Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly
Philippe Chanson et al.
CLINICAL ENDOCRINOLOGY (2008)
Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy
Annamaria Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: A prospective, randomized trial
Sven M. Carlsen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Long-term efficacy and safety of combined treatment of somatostatin analogs and Pegvisomant in acromegaly
Sebastian J. C. M. M. Neggers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Optimalization and cost management of lanreotide-Autogel therapy in acromegaly
Pascale Abrams et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Raquel S. Jallad et al.
CLINICAL ENDOCRINOLOGY (2007)
A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
Moises Mercado et al.
CLINICAL ENDOCRINOLOGY (2007)
Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study
I. Schreiber et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage
R Cozzi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on lGF-I levels, tumor mass, hypertension and glucose tolerance
A Colao et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly
A Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Long-acting somatostatin analog therapy of acromegaly: A meta- analysis
PU Freda et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
CLINICAL REVIEW: A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly
S Melmed et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly
J Feenstra et al.
LANCET (2005)
Presurgical octreotide treatment in acromegaly:: no improvement of final growth hormone (GH) concentration and pituitary function.: A long-term case-control study
U Plöckinger et al.
ACTA NEUROCHIRURGICA (2005)
Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs
P Petrossians et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Gamma-knife radiosurgery in acromegaly: A 4-year follow-up study
R Attanasio et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Long-term effects of lanreotide SR and octreotide LAR (R) on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly
G Amato et al.
CLINICAL ENDOCRINOLOGY (2002)
Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre
T Abe et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2001)
Share Paper
